

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 77039

Title: 192 weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04025443

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Doctor, Senior Researcher

Reviewer's Country/Territory: Russia

Author's Country/Territory: China

Manuscript submission date: 2022-04-13

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-05-04 02:52

Reviewer performed review: 2022-05-05 11:06

Review time: 1 Day and 8 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Dear authors! I read with interest your manuscript entitled "192 weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C" which is based on the data obtained in double-blind prospective study and provides follow-up information to previously published results (J Viral Hepat. 2017 Oct;24(10):877-884. doi: 10.1111/jvh.12710), where the same cohort was assessed at wk 144 and 2 reports of the assessment at wk 48. According to the results, entecavir maleat shows potent viral suppression and has good safety profile. However, the study design undermines that subjects received open-label treatment with entecavir maleat after wk 49. This makes the novelty of the results questionable as comparative efficacy has already been reported in 3 publications. Moreover, the current data are in conflict with the previously reported in terms of HBV DNA decline from baseline: at wk 144 for HBe-negative group it was (by 6.13 log₁₀ IU/mL vs B: by 5.65 log₁₀ IU/mL), whereas now it turned out to be 6.05 log₁₀ IU/mL vs. 6.03 log₁₀ IU/mL, accordingly, while the number of subjects remained unchanged and the percentage of people with undetectable HBV DNA was 100% at both points. As mentioned in previous review of unpublished manuscript 74505, where the data of 240 weeks of entecavir maleat were discussed, efficacy of treatment with NUCs may depend on liver fibrosis. Although no assessment of liver fibrosis with histological examination and/or liver stiffness measurement was performed initially, it may be possible to retrieve these data based on blood tests (for example, Fib-4, APRI, Forns index etc). The data about concomitant medications and analysis of compliance should be given as well. Please, provide the data on the set of primers used for PCR analysis. It is not clear why to include the data of patient who



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

developed resistance to entecavir at week 96 to the final analysis, as further effect of treatment (decline of HBV DNA level) is caused by the switch to ADV (not the effect of ETV maleat) Please, provide clear Clinical trial registration statement. Table 2 is not organized according to 3-lines requirement. Please, remove in-built footnotes from tables 1, 3 and 4. The study obviously had supportive foundation, please, revise the statement on the page 2. The manuscript requires language polishing and formatting according to the journal requirements.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 77039

Title: 192 weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05261046

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: United States

Author's Country/Territory: China

Manuscript submission date: 2022-04-13

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-05-08 01:36

Reviewer performed review: 2022-05-08 01:38

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

Excellent topic. Please revise for grammar errors.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 77039

Title: 192 weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04737076

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Consultant Physician-Scientist, Doctor, Lecturer, Pediatric Gastroenterology Fellow, Professor, Senior Postdoctoral Fellow, Senior Researcher, Senior Scientist

Reviewer's Country/Territory: Russia

Author's Country/Territory: China

Manuscript submission date: 2022-04-13

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-05-05 07:43

Reviewer performed review: 2022-05-13 08:37

Review time: 8 Days

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection

Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The title of the manuscript fully reflects the content. The abstract and keywords summarize the content of the manuscript. The introduction is short, clear and understandable. The research methods are described in detail and quite well in the manuscript. The results of the study are described in detail and well. The discussion briefly, clearly and logically highlights the key points. The results are well presented, comparison of the results with previous studies and their relevance. The results of the study are very relevant for clinical practice. The charts and tables are of good quality and properly illustrate the content of the article. There are self-citations that could be avoided if a short summary of the previous data was included in the text. On the whole, the manuscript is well written, concise and consistent. On the whole, the manuscript is well written, concise and consistent, and meets ethical requirements.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 77039

Title: One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04025443

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Doctor, Senior Researcher

Reviewer's Country/Territory: Russia

Author's Country/Territory: China

Manuscript submission date: 2022-04-13

Reviewer chosen by: Yu-Lu Chen

Reviewer accepted review: 2022-06-29 07:57

Reviewer performed review: 2022-06-29 08:17

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Congratulations to the authors with the great job done. The manuscript was significantly improved and the authors provided satisfactory responses to my comments. Thank you.